Dabrafenib-Trametinib and Radiotherapy for Oligoprogressive <i>BRAF</i> Mutant Advanced Melanoma

The clinical management of metastatic melanoma has been changed by BRAF (BRAFi) and MEK inhibitors (MEKi), which represent a standard treatment for <i>BRAF</i>-mutant melanoma. In oligoprogressive melanoma patients with <i>BRAF</i> mutations, target therapy can be combined with loco-regional radioth...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Ernesto Rossi, Giovanni Schinzari, Francesco Cellini, Mario Balducci, Mariangela Pasqualoni, Brigida Anna Maiorano, Bruno Fionda, Silvia Longo, Francesco Deodato, Alessandro Di Stefani, Ketty Peris, Maria Antonietta Gambacorta, Giampaolo Tortora
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2023-01-01
Sarja:	Biomedicines
Aiheet:	metastatic melanoma BRAF inhibitors MEK inhibitors radiotherapy case series BRAF
Linkit:	https://www.mdpi.com/2227-9059/11/2/394
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!